--- title: "Cuprina Holdings (Cayman) (CUPR) news: offering" url: "https://aibio.space/companies/cuprina-cayman/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CUPR offering news: Cuprina closes over-allotment of 648,373 shares at $1.15, raising offering to about $5,716,491." --- CUPR Cuprina Holdings (Cayman) Limited NASDAQ · Singapore # Cuprina Holdings (Cayman) (CUPR) news CUPR offering news Financings · 2026-09-29 ## [Cuprina closes over-allotment of 648,373 shares at $1.15, raising offering to about $5,716,491](https://aibio.space/news/cuprina-closes-allotment-648-373-shares-1-15-raising-offering-about-5/) Cuprina closed the sale of 648,373 more Class A shares at $1.15 after the underwriter exercised its over-allotment option in full. Total gross proceeds reached about $5,716,491, and R. F. Lafferty & Co., Inc. was the sole book-running manager. ## Latest Cuprina Holdings (Cayman) news 1. 2026-06-12 Listings [Cuprina Holdings regains Nasdaq compliance, July 7, 2026 hearing cancelled](https://aibio.space/news/cuprina-holdings-regains-nasdaq-compliance-july-7-2026-hearing/) Cuprina said Nasdaq staff told its hearings department the bid price shortfall was cured, and a July 7, 2026 panel hearing was cancelled. The release does not say what moved the share price, and year-end cash was $2.4 million against cash used in operations of $7.1 million. 2. 2026-05-14 Listings [Cuprina shareholders approve share consolidation and higher Class B voting rights](https://aibio.space/news/cuprina-shareholders-approve-share-consolidation-higher-class-b-voting/) Cuprina holders approved a share consolidation, raised Class B votes from 10 to 100 per share and allowed share issues of 20% or more of Class A shares. About 2.79% of the Class A votes were represented at the meeting. 3. 2025-04-17 Distress [Cuprina Holdings files late notice for 2024 annual report on Form 20-F](https://aibio.space/news/cuprina-holdings-files-late-notice-2024-annual-report-form-20/) The Singapore-based company says it needs more time to finalize the report and plans to file within the fifteen-day grace period. ## Cuprina Holdings (Cayman) at a glance - **Ticker**: CUPR - **Listing**: NASDAQ - **Country**: Singapore - **Cash, Dec 31, 2025**: $2.4 million ### Related companies - [iX Biopharma](https://aibio.space/companies/ix-biopharma/) SGX: 42C - [Haw Par Corporation](https://aibio.space/companies/haw-par/) SGX: H02 - [Hyphens Pharma International](https://aibio.space/companies/hyphens-pharma-international/) SGX: 1J5 - [Prestige BioPharma](https://aibio.space/companies/prestige-biopharma/) KRX: 950210 - [Embracing Future Holdings](https://aibio.space/companies/embracing-future/) SGX: 8YY - [CytoMed Therapeutics](https://aibio.space/companies/cytomed-therapeutics/) NASDAQ: GDTC ### Also on NASDAQ - [Seer](https://aibio.space/companies/seer/) SEER - [Kamada](https://aibio.space/companies/kamada/) KMDA - [Jade Biosciences](https://aibio.space/companies/jade-biosciences/) JBIO - [PULSE BIOSCIENCES, INC.](https://aibio.space/companies/pulse-biosciences/) PLSE - [PharmaCyte Biotech](https://aibio.space/companies/pharmacyte-biotech/) PMCB - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) ORGO ## What Cuprina Holdings (Cayman) does Cuprina Holdings (Cayman) Limited operates mainly through its Singapore subsidiary, Cuprina Pte. Ltd., as a biomedical and biotechnology company. It develops and commercializes products for the management of chronic wounds and also operates in the health and beauty sector. Its commercial line, MEDIFLY, consists of medical grade sterile blowfly larvae bio-dressings used as a biological debridement tool in Maggot Debridement Therapy. Its pipeline includes three lines of chronic wound care products: collagen dressings made from bullfrog collagen under an exclusive license from NTU, iodine-based topical antiseptic products distributed under a joint venture with Aiodine Laboratory Pte. Ltd., and products using medical leeches. The company expects these to be developed over 2026 and 2027 and to become commercially available subject to regulatory approval. MEDIFLY is sold mainly in Singapore and, since March 2023, in Hong Kong, and its customers are mainly public and private hospitals and clinics in Singapore. It also sells cosmeceutical products introduced in 2023 and plans to expand into the Middle East, including the Gulf Cooperation Council states, and mainland China. | Product or program | What it is | Stage | |---|---|---| | MEDIFLY | Medical grade sterile blowfly larvae bio-dressings for chronic wound debridement | commercialized | | Bullfrog collagen dressings | Collagen sponges, particles and hydrogels for chronic wounds, under an NTU license | in development, expected commercially available 2026 and 2027 subject to regulatory approval | | Iodine-based antiseptic products | Iodine-based wound care and topical antiseptic products, distributed through a joint venture | in development, expected commercially available 2026 and 2027 subject to regulatory approval | | Medical leech products | Products utilizing medical leeches for wound treatment | in development, expected commercially available 2026 and 2027 subject to regulatory approval | | Cosmeceutical products | Hydrating balm, muscle energy cream and pain relief muscle patch introduced in 2023 | commercialized | Summarised from the company's [20-F filed Apr 27, 2026](https://www.sec.gov/Archives/edgar/data/1995704/000149315226019085/form20-f.htm). ## Cuprina Holdings (Cayman) annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$38,789](https://www.sec.gov/Archives/edgar/data/1995704/000149315226019085/) | [$35,522](https://www.sec.gov/Archives/edgar/data/1995704/000164117225010302/) | | Research and development | [$176,385](https://www.sec.gov/Archives/edgar/data/1995704/000149315226019085/) | [$177,433](https://www.sec.gov/Archives/edgar/data/1995704/000164117225010302/) | | Net income (loss) | [-$3.6 million](https://www.sec.gov/Archives/edgar/data/1995704/000149315226019085/) | [-$1.1 million](https://www.sec.gov/Archives/edgar/data/1995704/000164117225010302/) | | Cash from operations | [-$7.1 million](https://www.sec.gov/Archives/edgar/data/1995704/000149315226019085/) | [-$908,609](https://www.sec.gov/Archives/edgar/data/1995704/000164117225010302/) | | Cash and equivalents | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1995704/000149315226019085/) | [$85,622](https://www.sec.gov/Archives/edgar/data/1995704/000164117225010302/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $2.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cuprina Holdings (Cayman) Has Cuprina Holdings (Cayman) raised money recently? Our latest story on this, dated Sep 29, 2026: "Cuprina closes over-allotment of 648,373 shares at $1.15, raising offering to about $5,716,491". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cuprina-closes-allotment-648-373-shares-1-15-raising-offering-about-5/). What is the ticker symbol of Cuprina Holdings (Cayman)? Cuprina Holdings (Cayman) Limited trades under the ticker CUPR on NASDAQ. Where is Cuprina Holdings (Cayman) listed? Cuprina Holdings (Cayman) Limited is listed on NASDAQ. What is the SEC CIK of Cuprina Holdings (Cayman)? The SEC Central Index Key (CIK) for Cuprina Holdings (Cayman) Limited is 1995704. Its filings are on SEC EDGAR. How many shares does Cuprina Holdings (Cayman) have outstanding? 7,365,000 shares as of 2026-04-27, per the cover page of its 20-F filed 2026-04-27. Which country or territory is Cuprina Holdings (Cayman) listed under? Our directory records Cuprina Holdings (Cayman) Limited under Singapore. What does Cuprina Holdings (Cayman) do? Our directory classifies Cuprina Holdings (Cayman) Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Cuprina Holdings (Cayman)? The ISIN recorded for Cuprina Holdings (Cayman) Limited is KYG2592E1109. Does aibio.space cover Cuprina Holdings (Cayman)? aibio.space lists Cuprina Holdings (Cayman) Limited among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cuprina Holdings (Cayman) incorporated? SEC records list its state or country of incorporation as E9. What does Cuprina Holdings (Cayman) develop? Cuprina Holdings (Cayman) Limited operates mainly through its Singapore subsidiary, Cuprina Pte. Ltd., as a biomedical and biotechnology company. What is MEDIFLY from Cuprina Holdings (Cayman)? MEDIFLY: Medical grade sterile blowfly larvae bio-dressings for chronic wound debridement Stage: commercialized. What is Bullfrog collagen dressings from Cuprina Holdings (Cayman)? Bullfrog collagen dressings: Collagen sponges, particles and hydrogels for chronic wounds, under an NTU license Stage: in development, expected commercially available 2026 and 2027 subject to regulatory approval. What was Cuprina Holdings (Cayman)'s revenue last year? $38,789 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Cuprina Holdings (Cayman) profitable? Cuprina Holdings (Cayman) Limited reported a net loss of $3.6 million for the fiscal year ended Dec 31, 2025, and used $7.1 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Cuprina Holdings (Cayman) Members talk about Cuprina Holdings (Cayman) (CUPR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cuprina Holdings (Cayman), newest first. Each line links the filing it comes from. 1. 2026-09-29 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000149315226044861/ex99-1.htm) 2. 2026-09-16 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000149315226042872/form424b4.htm) 3. 2026-07-07 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000149315226032280/formf-1.htm) 4. 2026-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000149315226028381/ex99-1.htm) 5. 2026-05-14 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000149315226022902/form6-k.htm) 6. 2026-04-21 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000149315226018225/ex99-1.htm) 7. 2025-11-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000149315225025313/ex99-1.htm) 8. 2025-05-08 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000164117225009201/ex99-1.htm) 9. 2025-04-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000164117225005153/formnt20-f.htm) 10. 2025-04-10 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000164117225003511/form424b4.htm) 11. 2024-12-06 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1995704/000149315224049003/formf-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CUPR on TradingView](https://www.tradingview.com/symbols/NASDAQ-CUPR/). ## SEC filings and registration - **SEC name**: Cuprina Holdings (Cayman) LTD - **CIK**: 1995704 - **Industry (SIC)**: Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) - **US tickers**: CUPR (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: BLOCK 1090, SINGAPORE, Singapore, 169201 - **Phone**: (65) 8512 7275 - **Shares outstanding**: 7,365,000 as of 2026-04-27 (20-F filed 2026-04-27) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1995704/000149315226047714/form6-k.htm) filed 2026-10-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1995704/000149315226045444/form6-k.htm) filed 2026-10-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1995704/000149315226044861/form6-k.htm) filed 2026-09-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1995704/000149315226043258/form6-k.htm) filed 2026-09-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1995704/000149315226043204/form6-k.htm) filed 2026-09-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1995704/000149315226028628/form6-k.htm) filed 2026-06-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1995704/000149315226028381/form6-k.htm) filed 2026-06-12 - [6-K](https://www.sec.gov/Archives/edgar/data/1995704/000149315226022902/form6-k.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001995704), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cuprina Holdings (Cayman) Limited is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CUPR, recorded under Singapore. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cuprina Holdings (Cayman) Limited - **Ticker**: CUPR - **Listing**: NASDAQ - **Country or territory**: Singapore - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG2592E1109 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CUPR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cuprina-cayman/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cuprina Holdings (Cayman) (CUPR) news: offering", 2026-10-31, https://aibio.space/companies/cuprina-cayman/